$PBIO First Issued U.S. Patent Advances the Company Toward 2021 Product Delivery, Significant Acceleration of Revenue, and Profitability

• Life sciences technology innovator Pressure BioSciences (OTCQB: PBIO) has increased its IP stable to 26 patents worldwide with the announcement of its first U.S. patent for its revolutionary Ultra Shear Technology(TM) (“UST”) Platform
• The patent (US 10,823,159) – entitled “System for High Pressure, High Shear Processing of Fluids” – will be the framework of the company’s new instrument line (the BaroShear K45 Nanoemulsification System) to be commercially released in mid-2021
• UST is expected to revolutionize the processing of immiscible liquids into high quality, highly profitable nanoemulsions
• Nanoemulsions are highly sought after in a variety of industries because of their ability to improve stability, appearance, taste, and/or water solubility of retail products (e.g., food, beverages, cosmetics) as well as for the delivery and bioavailability of biopharmaceutical drugs and vaccines
• The legal cannabidiol (“CBD”) industry has been particularly attractive to the company because of its nascent and enormous popularity, leading to projections from multiple sources that it will surge to a $47 billion market by 2025
• Pressure BioSciences expects to deliver on the preorder of its first dozen BaroShear K45 Systems during the first half of next year, which is expected to generate additional revenue for the company of about $3 million, and that is just for the first half of 2021

Pressure BioSciences (OTCQB: PBIO) recently announced the issuance of the first U.S. patent for its  innovative Ultra Shear Technology (UST) platform  that utilizes ultra high pressure and intense shearing forces to make unique, high-quality nanoemulsions that have enormous use in a wide variety of industries. The announcement brings PBI’s IP patent portfolio up to 26 worldwide and should move the company rapidly towards significantly increased revenue and profitability.

The patent for the company’s trademarked Ultra Shear Technology (“UST”) platform entitled “System for High Pressure, High Shear Processing of Fluids” is the first long-term patent (20-year) for UST in the world, and takes Pressure BioSciences another step closer toward its mid-2021 planned commercial release of the BaroShear K45 System, which will be the company’s first UST-based processing system to reach the market (https://ibn.fm/ozzPZ).

The UST platform was created to revolutionize the process of mixing liquids that normally do not mix, such as oil and water, but without the need for high quantities of chemicals that are all too common in today’s nanoemulsions. The chemically emulsified mixtures of these liquids currently have wide use in everyday products, such as foods, pharmaceutical drugs and nutraceuticals, cosmetics, industrial lubricants and most recently cannabis oil extracts that are becoming increasingly popular with legalization.  PBI’s UST processed nanoemulsions are expected to exceed the quality of today’s chemically-produced nanoemulsions, while decreasing the cost of manufacture and minimizing the need for large amounts of added chemicals.

Nano particles offer a large surface area in relation to their volume due to their small size, which provides them with special chemical, physical and biological properties in contrast to bulk matter at normal scale (https://ibn.fm/sJn1N).

While nano particles are currently used in high-quality items like scratch-proof glasses and transparent sunscreens, their medical applications are perhaps of greatest interest. Drug makers look to nano emulsions as a means of transporting medicines to specifically targeted disease cells, such as cancers, reducing damage to nearby healthy ones. Lipid-based nano particles (“LNP”) are increasingly sought after as vaccine carriers for preventative medical purposes as well.  PBI’s UST nanoemulsification platform offers the potential to quickly and successfully compete in these existing areas, because of its many advantages over current processes.

The hemp-derived cannabidiol (“CBD”) market’s pursuit of efficient nanoemulsification for superior delivery, absorption, and bioavailability of its oil-based nutraceuticals is also a potentially very lucrative market because changing perspectives toward cannabis worldwide have created a booming nascent industry. Cannabis market research firm BDS Analytics CEO Roy Bingham predicts legal CBD will become a $47 billion market by 2025 (https://ibn.fm/xZllS).

“Nanoemulsions have long been shown to exhibit improved absorption, higher bioavailability, and greater stability, while often requiring lower levels of emulsifiers than macro/micro emulsion products,” Senior Vice President of Engineering Dr. Edmund Y. Ting stated in the company announcement. “Because of these significant advantages, nanoemulsions are currently the focus of numerous research efforts worldwide. However, cost-effective scale-up of high quality nanoemulsion processing at a commercial level continues to be quite challenging. Importantly, we believe that PBI’s innovative and now patented UST platform can provide the key to commercial success for nanoemulsion products.”

The company has received pre-orders for 12 BaroShear K45 systems, which it plans to deliver during the first half of 2021 for up to $3 million in additional revenue (https://ibn.fm/TgON9). Pressure BioSciences also is in talks with academic organizations and government agencies that have expressed interest in the UST platform for other product and research possibilities, such as an alternative for processing fresh milk, juices, and other dairy products into a long-term stable, room temperature, tasty products.

For more information, visit the company’s website at www.PressureBioSciences.com.

NOTE TO INVESTORS: The latest news and updates relating to PBIO are available in the company’s newsroom at http://ibn.fm/PBIO

About InvestorWire

InvestorWire is the wire service that gives you more. From regional releases to global announcements presented in multiple languages, we offer the wire-grade dissemination products you’ll need to ensure that your next press release grabs the attention of your target audience and doesn’t let go. While our competitors look to nickel and dime you with hidden fees and restrictive word limits, InvestorWire keeps things transparent. We offer UNLIMITED Words on all domestic releases. While other wire services may provide a basic review of your release, InvestorWire helps you put your best foot forward with complimentary Press Release Enhancement.

With our competitors, the work is done the second your release crosses the wire. Not with InvestorWire. We include follow-up coverage of every release by leveraging the ever-expanding audiences of the 50+ brands that make up the InvestorBrandNetwork.

Get more out of your next press release with InvestorWire. It’s unlike anything you’ve seen before.

For more information, please visit https://www.InvestorWire.com

Please see full terms of use and disclaimers on the InvestorBrandNetwork website applicable to all content provided by IBN, wherever published or re-published: http://ibn.fm/Disclaimer

InvestorWire (IW)
8033 Sunset Blvd Suite 1037-IW
Los Angeles, CA 90046
310.299.1717 Office
www.InvestorWire.com
Editor@InvestorWire.com

InvestorWire is part of the InvestorBrandNetwork.